Come to Kai Medicine: US FDA Accepts Clinical Trial Application for New Drug LAE118.

On the morning of January 14th, Laike Pharmaceutical announced on the Hong Kong Stock Exchange that the U.S. Food and Drug Administration has accepted the new drug clinical trial application for LAE118. LAE118 is a novel PI3K pan-mutant selective inhibitor used to treat solid tumor patients with PIK3CA mutations.